The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • LBT Innovations (LBT) has announced the first placement of APAS Independence in a U.K. lab
  • The company’s APAS Independence has been installed and commissioned at the state-of-the-art Health Sciences Laboratory (HSL) in London
  • HSL will evaluate the utility of APAS Independence and its potential to be integrated into its current solutions
  • APAS Independence is a platform technology that automates and speeds up culture plate screening
  • LBT is up 3.23 per cent on the market and shares are trading for 16 cents each

Meditech company LBT Innovations (LBT) has announced the first placement of APAS Independence in a U.K. lab.

The company’s APAS Independence has been installed and commissioned at the state-of-the-art Health Sciences Laboratory (HSL) in London.

The laboratory is a clinically led provider of pathology and diagnostic services and delivers innovation and value to the healthcare sector.

HSL will evaluate the utility of APAS Independence and its potential to be integrated into its current solutions.

APAS Independence at the Health Services Laboratory
Source: LBT Innovations

It will be installed alongside HSL’s current solutions and following initial training, and an evaluation will be carried out over a three-month period.

“We are extremely excited to be the first in the U.K. to trial the APAS Independence,” Head of Department, Infection Sciences at HSL Alan Spratt said.

“The application of assisted intelligence in a high-volume lab like ours has the potential to streamline laboratory workflows bringing benefits to staff, quality, turnaround times and consequentially patient outcomes,” he added.

APAS (Automated Plate Assessment System) Independence is a platform technology that automates culture plate screening and interpretation.

Thousands of culture plates are assessed everyday and currently each one has to be thoroughly examined. This can take time and may be subject to common human error.

APAS Independence speeds-up this process by automatically screening, interpreting and sorting the plates.

“Installation of the first APAS Independence in the U.K. represents another step forward in the commercialisation of the technology in Europe,” LBT CEO and Managing Director Brent Barnes commented.

“It was particularly pleasing to see the teams work closely together to complete the remote installation of the APAS instrument. This reflects the simple modular design of the technology and demonstrates how the company can continue to engage with customers whilst COVID-19 travel restrictions remain in place,” he added.

LBT is up 3.23 per cent on the market and shares are trading for 16 cents each at 12:25 pm AEST.

lbt by the numbers
More From The Market Online

Emvision Medical Devices unlocks traumatic brain injury First Responder with $3m grant

EMVision Medical Devices has been awarded a $3 million grant the Australian government’s national CRC-P program.

Immutep obtains encouraging disease-free survival in phase II sarcoma trial

Immutep has unveiled new data from the investigator-initiated EFTISARC-NEO Phase II study evaluating radiotherapy before surgery.

Xenitra signs JD Health strategic Chinese agreement targeting $100m in sales

Xenitra subsidiary Shengdi Pharmaceutical has entered into a three-year strategic agreement with China’s largest online healthcare…

Racura Oncology receives positive results in study of RC110 and RC220

Racura Oncology has obtained positive results from a study into RC220, the company’s proprietary formulation of…